1 World Health Organization. Weekly Epidemiological Update on COVID-19: Edition 50. Geneva: WHO; 2021.
2 Wu F, Zhao S, Yu B et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579: 265–9.
3 Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: Where do we stand in 2021? Paediatr. Respir. Rev. 2021; 39: 22–31.
4 Nguyen HL, Lan PD, Thai NQ, Nissley DA, O’Brien EP, Li MS. Does SARS-CoV-2 bind to human ACE2 more strongly than does SARSCoV? J. Phys. Chem. B 2020; 124: 7336–47.
5 Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Critical Care (London, England) 2021; 25: 244.
6 Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020; 323: 2427–9.
7 Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect 2020; 53: 371–2.
8 Tosif S, Neeland MR, Sutton P et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat. Commun. 2020; 11: 5703.
9 Loske J, Röhmel J, Lukassen S et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat. Biotechnol. 2021 https://doi.org/10.1038/s41587-021-01037-9.
10 Neeland MR, Bannister S, Clifford V et al. Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. Nat. Commun. 2021; 12: 1084.
11 Weisberg SP, Connors TJ, Zhu Y et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 2021; 22: 25–31.
12 Selva KJ, van de Sandt CE, Lemke MM et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat. Commun. 2021; 12: 2037.
13 Bacher P, Rosati E, Esser D et al. Low-avidity CD4(+) T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity 2020; 53: 1258–71.
14 Palmer DB. The effect of age on thymic function. Front. Immunol.2013; 4: 316.
15 Korakas E, Ikonomidis I, Kousathana F et al. Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes. Am. J. Physiol. Endocrinol. Metab. 2020; 319: E105.
16 Migliorini F, Torsiello E, Spiezia F, Oliva F, Tingart M, Maffulli N. Association between HLA genotypes and COVID-19 susceptibility, severity and progression: A comprehensive review of the literature. Eur. J. Med. Res. 2021; 26: 84.
17 Langton DJ, Bourke SC, Lie BA et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA 2021; 98: 14–22.
18 Wurzel D et al. COVID-19 and its multi-system inflammatory complications in children - a multi-centre nationwide Australian study. BMJ Open. 2021; in press
19 Liguoro I, Pilotto C, Bonanni M et al. SARS-COV-2 infection in children and newborns: A systematic review. Eur. J. Pediatr. 2020; 179: 1029–46.
20 Feldstein LR, Rose EB, Horwitz SM et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 2020; 383: 334–46.
21 Whittaker E, Bamford A, Kenny J et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324: 259–69.
22 Viner RM, Ward JL, Hudson LD et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch. Dis. Child. 2020; 106: 802–7.
23 Irfan O, Muttalib F, Tang K, Jiang L, Lassi ZS, Bhutta Z. Clinical characteristics, treatment and outcomes of paediatric COVID-19: A systematic review and meta-analysis. Arch. Dis. Child. 2021; 106: 440–8.
24 Molteni E, Sudre CH, Canas LS et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health 2021; 5: 708–18.
25 Götzinger F, Santiago-García B, Noguera-Julian A et al. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; 4: 653–61.
26 Parcha V, Booker KS, Kalra R et al. A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States. Sci. Rep. 2021; 11: 10231.
27 Gale C, Quigley MA, Placzek A et al. Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: A prospective national cohort study using active surveillance. Lancet Child Adolesc Health 2021; 5: 113–21.
28 Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061–9.
29 Cui X, Zhao Z, Zhang T et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J. Med. Virol. 2021; 93: 1057–69.
30 Brisca G, Mallamaci M, Tardini G et al. SARS-CoV-2 infection may present as acute hepatitis in children. Pediatr. Infect. Dis. J. 2021; 40: e214–5.
31 Ray STJ, Abdel-Mannan O, Sa M et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: A prospective national cohort study. Lancet Child Adolesc Health 2021; 5: 631–41.
32 Abi Nassif T, Fakhri G, Younis NK et al. Cardiac manifestations in COVID-19 patients: A focus on the pediatric population. Can. J. Infect. Dis. Med. Microbiol. 2021; 2021: 5518979.
33 Toubiana J, Poirault C, Corsia A et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: Prospective observational study. BMJ (Clin Res ed) 2020; 369: m2094.
34 Williams PCM, Howard-Jones AR, Hsu P et al. SARS-CoV-2 in children: Spectrum of disease, transmission and immunopathological underpinnings. Pathology 2020; 52: 801–8.
35 Feldstein LR, Tenforde MW, Friedman KG et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021; 325: 1074–87.
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.